Functional analysis of patient-derived mutations in the Fanconi anemia gene, FANCG/XRCC9

Koji Nakanishi, Anna Moran, Tobias Hays, Yanan Kuang, Edward Fox, Danielle Garneau, Rocio Montes De Oca, Markus Grompe, Alan D. D'Andrea

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective. Fanconi anemia (FA) is an autosomal-recessive cancer susceptibility syndrome with seven complementation groups. Six of the FA genes have been cloned (corresponding to subtypes A, C, D2, E, F, and G) and the encoded proteins interact in a common pathway. Patient-derived mutations in FA genes have been helpful in delineating functional domains of FA proteins. The purpose of this work was to subtype FA patient-derived cell lines in our repository and to identify FA gene mutations. Methods. We subtyped 62 FA patients as type A, G, C, or non-ACG by using a combination of retroviral gene transfer and immunoblot analysis. Among these FA patients, we identified six FA-G patients for further analysis. We used a strategy involving amplification of FANCG/XRCC9 exons and direct sequencing to identify novel FANCG mutations in cell lines derived from these FA-G patients. We functionally analyzed FANCG mutant alleles by transducing the corresponding cDNAs into a known FA-G indicator cell line and scoring correction of MMC sensitivity. Results. Our results demonstrate a wide range of mutations in the FANCG gene (splice, nonsense, and missense mutations). Based on this mutational screen, a carboxy terminal functional domain of the FANCG protein appears to be required for complementation of FA-G cells and for normal assembly of the FANCA/FANCG/FANCC protein complex. Conclusion. The identification of patient-derived mutant alleles of FA genes can provide important insights to the function of FA proteins. FA subtyping is also a necessary precondition for gene therapy.

Original languageEnglish (US)
Pages (from-to)842-849
Number of pages8
JournalExperimental Hematology
Volume29
Issue number7
DOIs
StatePublished - 2001

Fingerprint

Fanconi Anemia
Mutation
Genes
Fanconi Anemia Complementation Group G Protein
Fanconi Anemia Complementation Group Proteins
Gastrin-Secreting Cells
Cell Line
Fanconi Anemia Complementation Group C Protein
Alleles
Nonsense Codon
Missense Mutation
Genetic Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Hematology
  • Oncology
  • Transplantation

Cite this

Nakanishi, K., Moran, A., Hays, T., Kuang, Y., Fox, E., Garneau, D., ... D'Andrea, A. D. (2001). Functional analysis of patient-derived mutations in the Fanconi anemia gene, FANCG/XRCC9. Experimental Hematology, 29(7), 842-849. https://doi.org/10.1016/S0301-472X(01)00663-4

Functional analysis of patient-derived mutations in the Fanconi anemia gene, FANCG/XRCC9. / Nakanishi, Koji; Moran, Anna; Hays, Tobias; Kuang, Yanan; Fox, Edward; Garneau, Danielle; De Oca, Rocio Montes; Grompe, Markus; D'Andrea, Alan D.

In: Experimental Hematology, Vol. 29, No. 7, 2001, p. 842-849.

Research output: Contribution to journalArticle

Nakanishi, K, Moran, A, Hays, T, Kuang, Y, Fox, E, Garneau, D, De Oca, RM, Grompe, M & D'Andrea, AD 2001, 'Functional analysis of patient-derived mutations in the Fanconi anemia gene, FANCG/XRCC9', Experimental Hematology, vol. 29, no. 7, pp. 842-849. https://doi.org/10.1016/S0301-472X(01)00663-4
Nakanishi, Koji ; Moran, Anna ; Hays, Tobias ; Kuang, Yanan ; Fox, Edward ; Garneau, Danielle ; De Oca, Rocio Montes ; Grompe, Markus ; D'Andrea, Alan D. / Functional analysis of patient-derived mutations in the Fanconi anemia gene, FANCG/XRCC9. In: Experimental Hematology. 2001 ; Vol. 29, No. 7. pp. 842-849.
@article{d5989b3876974d32b8dfa6f181186478,
title = "Functional analysis of patient-derived mutations in the Fanconi anemia gene, FANCG/XRCC9",
abstract = "Objective. Fanconi anemia (FA) is an autosomal-recessive cancer susceptibility syndrome with seven complementation groups. Six of the FA genes have been cloned (corresponding to subtypes A, C, D2, E, F, and G) and the encoded proteins interact in a common pathway. Patient-derived mutations in FA genes have been helpful in delineating functional domains of FA proteins. The purpose of this work was to subtype FA patient-derived cell lines in our repository and to identify FA gene mutations. Methods. We subtyped 62 FA patients as type A, G, C, or non-ACG by using a combination of retroviral gene transfer and immunoblot analysis. Among these FA patients, we identified six FA-G patients for further analysis. We used a strategy involving amplification of FANCG/XRCC9 exons and direct sequencing to identify novel FANCG mutations in cell lines derived from these FA-G patients. We functionally analyzed FANCG mutant alleles by transducing the corresponding cDNAs into a known FA-G indicator cell line and scoring correction of MMC sensitivity. Results. Our results demonstrate a wide range of mutations in the FANCG gene (splice, nonsense, and missense mutations). Based on this mutational screen, a carboxy terminal functional domain of the FANCG protein appears to be required for complementation of FA-G cells and for normal assembly of the FANCA/FANCG/FANCC protein complex. Conclusion. The identification of patient-derived mutant alleles of FA genes can provide important insights to the function of FA proteins. FA subtyping is also a necessary precondition for gene therapy.",
author = "Koji Nakanishi and Anna Moran and Tobias Hays and Yanan Kuang and Edward Fox and Danielle Garneau and {De Oca}, {Rocio Montes} and Markus Grompe and D'Andrea, {Alan D.}",
year = "2001",
doi = "10.1016/S0301-472X(01)00663-4",
language = "English (US)",
volume = "29",
pages = "842--849",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Functional analysis of patient-derived mutations in the Fanconi anemia gene, FANCG/XRCC9

AU - Nakanishi, Koji

AU - Moran, Anna

AU - Hays, Tobias

AU - Kuang, Yanan

AU - Fox, Edward

AU - Garneau, Danielle

AU - De Oca, Rocio Montes

AU - Grompe, Markus

AU - D'Andrea, Alan D.

PY - 2001

Y1 - 2001

N2 - Objective. Fanconi anemia (FA) is an autosomal-recessive cancer susceptibility syndrome with seven complementation groups. Six of the FA genes have been cloned (corresponding to subtypes A, C, D2, E, F, and G) and the encoded proteins interact in a common pathway. Patient-derived mutations in FA genes have been helpful in delineating functional domains of FA proteins. The purpose of this work was to subtype FA patient-derived cell lines in our repository and to identify FA gene mutations. Methods. We subtyped 62 FA patients as type A, G, C, or non-ACG by using a combination of retroviral gene transfer and immunoblot analysis. Among these FA patients, we identified six FA-G patients for further analysis. We used a strategy involving amplification of FANCG/XRCC9 exons and direct sequencing to identify novel FANCG mutations in cell lines derived from these FA-G patients. We functionally analyzed FANCG mutant alleles by transducing the corresponding cDNAs into a known FA-G indicator cell line and scoring correction of MMC sensitivity. Results. Our results demonstrate a wide range of mutations in the FANCG gene (splice, nonsense, and missense mutations). Based on this mutational screen, a carboxy terminal functional domain of the FANCG protein appears to be required for complementation of FA-G cells and for normal assembly of the FANCA/FANCG/FANCC protein complex. Conclusion. The identification of patient-derived mutant alleles of FA genes can provide important insights to the function of FA proteins. FA subtyping is also a necessary precondition for gene therapy.

AB - Objective. Fanconi anemia (FA) is an autosomal-recessive cancer susceptibility syndrome with seven complementation groups. Six of the FA genes have been cloned (corresponding to subtypes A, C, D2, E, F, and G) and the encoded proteins interact in a common pathway. Patient-derived mutations in FA genes have been helpful in delineating functional domains of FA proteins. The purpose of this work was to subtype FA patient-derived cell lines in our repository and to identify FA gene mutations. Methods. We subtyped 62 FA patients as type A, G, C, or non-ACG by using a combination of retroviral gene transfer and immunoblot analysis. Among these FA patients, we identified six FA-G patients for further analysis. We used a strategy involving amplification of FANCG/XRCC9 exons and direct sequencing to identify novel FANCG mutations in cell lines derived from these FA-G patients. We functionally analyzed FANCG mutant alleles by transducing the corresponding cDNAs into a known FA-G indicator cell line and scoring correction of MMC sensitivity. Results. Our results demonstrate a wide range of mutations in the FANCG gene (splice, nonsense, and missense mutations). Based on this mutational screen, a carboxy terminal functional domain of the FANCG protein appears to be required for complementation of FA-G cells and for normal assembly of the FANCA/FANCG/FANCC protein complex. Conclusion. The identification of patient-derived mutant alleles of FA genes can provide important insights to the function of FA proteins. FA subtyping is also a necessary precondition for gene therapy.

UR - http://www.scopus.com/inward/record.url?scp=0034948865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034948865&partnerID=8YFLogxK

U2 - 10.1016/S0301-472X(01)00663-4

DO - 10.1016/S0301-472X(01)00663-4

M3 - Article

C2 - 11438206

AN - SCOPUS:0034948865

VL - 29

SP - 842

EP - 849

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 7

ER -